Trial of Divalproex for Bipolar Disorder
Abstract
The safety and effectiveness of divalproex sodium (Depakapote®) in the treatment of 40 children and adolescents, aged 7 to 19 years, with a primary diagnosis of bipolar disorder were evaluated by open-label study (2-8 weeks) at the University of Texas, Galveston; University of Pennsylvania, Philadelphia; SUNY Stonybrook, NY; Massachusetts General Hospital, Boston; and University of Texas, San Antonio.
DOI: https://doi.org/10.15844/pedneurbriefs-16-10-2 | Journal eISSN: 2166-6482
Language: English
Page range: 74 - 74
Published on: Oct 1, 2002
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
Keywords:
© 2002 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.